Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

Background Levodopa is the most used and effective medication for motor symptoms of Parkinson disease (PD), its long-term use is associated with the appearance of levodopa-induced dyskinesia (LID). Uric acid (UA) is believed to play an important neuroprotective role in PD. Objective To in...

Full description

Bibliographic Details
Main Authors:	Nayron Medeiros Soares, Gabriela Magalhães Pereira, Ana Carolina Leonardi Dutra, Nathalie Ribeiro Artigas, Júlia Schneider Krimberg, Bruno Elkfury Monticelli, Artur Francisco Schumacher-Schuh, Rosa Maria Martins de Almeida, Carlos Roberto de Mello Rieder
Format:	Article
Language:	English
Published:	Academia Brasileira de Neurologia (ABNEURO) 2023-01-01
Series:	Arquivos de Neuro-Psiquiatria
Subjects:	parkinson disease uric acid dyskinesias levodopa
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1761294

Similar Items

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
by: Paolo Calabresi, et al.
Published: (2019-12-01)

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
by: Ritam Bandopadhyay, et al.
Published: (2022-04-01)

The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias
by: Vishakh Iyer, et al.
Published: (2021-11-01)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
by: Jinyoung Youn, et al.
Published: (2022-05-01)

Berberis vulgaris alleviates Levodopa-induced dyskinesia in male mice
by: Mokarian Faezeh, et al.
Published: (2018-12-01)

Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia
by: Mark M. Lin, et al.
Published: (2019-01-01)

Levodopa-induced belly dancer's dyskinesia: Case report
by: José Renan Miranda Cavalcante-Filho, et al.
Published: (2020-01-01)

Predictors of levo-dopa induced dyskinesias in Parkinson's disease
by: R T Athulya, et al.
Published: (2020-01-01)

Treatment of Levodopa-induced dyskinesia with Vitamin D: A Randomized, double-blind, placebo-controlled trial
by: Amir Hassan Habibi, et al.
Published: (2018-10-01)

Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation
by: Fanshi Zhang, et al.
Published: (2023-10-01)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
by: Destany K. Kwon, et al.
Published: (2022-11-01)

Potential efficacy of nanocurcumin on levodopa-induced dyskinesia in a rat parkinsonian model
by: Pegah Ashrafi, et al.
Published: (2022-11-01)

Radiomics and Hybrid Models Based on Machine Learning to Predict Levodopa-Induced Dyskinesia of Parkinson’s Disease in the First 6 Years of Levodopa Treatment
by: Yang Luo, et al.
Published: (2023-07-01)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
by: Michael H. Li, et al.
Published: (2018-11-01)

Relationship between physical exercise and the most varied forms of dyskinesia
by: Ana Elisa Speck, et al.
Published: (2021-04-01)

Striatal D1 Dopamine Neuronal Population Dynamics in a Rat Model of Levodopa-Induced Dyskinesia
by: Shasha Gao, et al.
Published: (2022-02-01)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018-04-01)

Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson’s disease
by: Jeongrak Park, et al.
Published: (2024-01-01)

Future Scenarios for Levodopa-induced Dyskinesias in Parkinson’s disease
by: Antonio eCerasa, et al.
Published: (2015-04-01)

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
by: Xuebing Cao, et al.

Riluzole Administration to Rats with Levodopa-Induced Dyskinesia Leads to Loss of DNA Methylation in Neuronal Genes
by: Luca Pagliaroli, et al.
Published: (2021-06-01)

Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia
by: Tatsuya Ueno, et al.
Published: (2014-04-01)

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia
by: Alberto Brugnoli, et al.
Published: (2016-01-01)

Brain-Region Specific Metabolic Abnormalities in Parkinson’s Disease and Levodopa-Induced Dyskinesia
by: Changwei Yang, et al.
Published: (2020-03-01)

Experimental study on the relationship between levodopa ⁃induced dyskinesia and phosphorylation of ERK in the striatum
by: Lu SONG, et al.
Published: (2011-02-01)

The features of sensorimotor integration in patients with levodopa-induced dyskinesia in Parkinson’s disease
by: Olga A. Alenikova, et al.
Published: (2017-02-01)

Efficacy of subthalamic deep brain stimulation for levodopa-induced dyskinesia in patients with Parkinson's disease: retrospective analysis of 12 cases
by: WANG Kuan, et al.
Published: (2020-12-01)

Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia
by: Rafael Rivas-Santisteban, et al.
Published: (2020-08-01)

Rhabdomyolysis Related to Dyskinesia in Parkinson’s Disease
by: Hesna Bektaş, et al.
Published: (2014-04-01)

Dose–response relationship of levodopa with dyskinesia in Parkinson's disease: A systematic review and meta-analysis
by: Taozhi He, et al.
Published: (2024-03-01)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01)

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia
by: Estefania Rojo-Bustamante, et al.
Published: (2018-10-01)

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
by: Jennifer Stanic, et al.
Published: (2017-12-01)

Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson’s disease
by: Joung Eun Kim, et al.
Published: (2023-11-01)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
by: Wu N, et al.
Published: (2018-07-01)

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease
by: Alfonsina Tirozzi, et al.
Published: (2021-04-01)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01)

Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
by: Lazzaro di Biase, et al.
Published: (2023-06-01)

Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats
by: Alberto Brugnoli, et al.
Published: (2020-10-01)